Avalo Therapeutics, Inc. — Form D

Avalo Therapeutics, Inc. of ROCKVILLE, MD, a company, filed a Form D exempt-offering notice with the SEC on 2024-04-09. The offering totals $200.0M, of which $130.6M was reported sold. Industry: Biotechnology.

Offering

Issuer

Officers, directors & promoters (52)

Showing 25 of 52 people.

NameRoleLocation
June Almenoff, M.D., Ph.D.DirectorRockville, MD
Mitchell ChanDirectorRockville, MD
Jonathan Goldman, M.D.DirectorRockville, MD
Aaron KantoffDirectorRockville, MD
Gilla Kaplan, Ph.D.DirectorRockville, MD
Garry Neil, M.D.DirectorRockville, MD
Magnus Persson, M.D., Ph.D.DirectorRockville, MD
Samantha TruexDirectorRockville, MD
Garry Neil, M.D.Executive OfficerRockville, MD
CHRISTOPHER SULLIVANExecutive OfficerNew York, NY
John KaiserExecutive OfficerResearch Triangle Park, NC
Behshad SheldonDirectorMalvern, PA
Eugene BauerDirectorRedwood City, CA
Magnus PerssonDirectorBeachwood, OH
Thomas AasenDirectorResearch Triangle Park, NC
Uli HacksellDirectorWAKE FOREST, NC
Uli HacksellExecutive OfficerWAKE FOREST, NC
Mariam MorrisExecutive OfficerDallas, TX
Isaac BlechDirectorJupiter, FL
Frank A TortiDirectorMenlo Park, CA
Isaac A BlechDirectorCITY OF INDUSTRY, CA
PHIL E GUTRYDirectorBALTIMORE, MD
MAGNUS E PERSSONDirectorBALTIMORE, MD
JOHN E KAISERExecutive OfficerBALTIMORE, MD
THOMAS E AASENDirectorBALTIMORE, MD

Other filings by this issuer (5)

FiledFormOfferingSold
2017-05-08D$5.0M$5.0M
2016-09-16D$15.0M$1.0M
2014-07-21D$33.3M$16.3M
2013-09-06D$10.0M$6.8M
2012-04-04D$22.5M$22.1M

More